Skip to main content
Journal cover image

Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.

Publication ,  Journal Article
O'Neal, WT; Sandesara, P; Hammadah, M; Venkatesh, S; Samman-Tahhan, A; Kelli, HM; Soliman, EZ
Published in: Am J Cardiol
June 1, 2017

Atrial fibrillation (AF) is associated with an increased risk for adverse events in patients with heart failure with preserved ejection fraction (HFpEF), but it is currently unknown if gender differences in these outcomes exist. To explore this hypothesis, we examined gender differences in the associations of AF with adverse outcomes in 3,385 (mean age 69 ± 9.6 years, 49% male, 89% white) patients with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Baseline AF cases were identified by self-reported history, medical record review, and baseline electrocardiogram data. Outcomes were adjudicated by a clinical end point committee and included the following: hospitalization, hospitalization for heart failure, stroke, death, and cardiovascular death. Cox regression was used to examine the risk of each outcome associated with AF. Over a median follow-up of 3.4 years, AF was associated with an increased risk for hospitalization (hazard ratio [HR] 1.49, 95% confidence interval [CI] 1.34 to 1.66), hospitalization for heart failure (HR 1.49, 95% CI 1.23 to 1.81), stroke (HR 2.10, 95% CI 1.43 to 2.09), death (HR 1.22, 95% CI 1.02 to 1.47), and cardiovascular death (HR 1.31, 95% CI 1.04 to 1.65). The association between AF and hospitalization was stronger in women (HR 1.63, 95% CI 1.40 to 1.91) than men (HR 1.37, 95% CI 1.18 to 1.58; p-interaction = 0.032). Although significant interactions were not observed for the other outcomes, we appreciated that the risk estimates were higher for women compared with men. In conclusion, AF increases the risk for adverse cardiovascular outcomes in patients with HFpEF, and the presence of this arrhythmia in women possibly is associated with a greater risk for adverse events than men.

Duke Scholars

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

June 1, 2017

Volume

119

Issue

11

Start / End Page

1785 / 1790

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Rate
  • Stroke Volume
  • Stroke
  • Spironolactone
  • Sex Factors
  • Sex Distribution
  • Risk Factors
  • Risk Assessment
 

Citation

APA
Chicago
ICMJE
MLA
NLM
O’Neal, W. T., Sandesara, P., Hammadah, M., Venkatesh, S., Samman-Tahhan, A., Kelli, H. M., & Soliman, E. Z. (2017). Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. Am J Cardiol, 119(11), 1785–1790. https://doi.org/10.1016/j.amjcard.2017.02.045
O’Neal, Wesley T., Pratik Sandesara, Muhammad Hammadah, Sanjay Venkatesh, Ayman Samman-Tahhan, Heval M. Kelli, and Elsayed Z. Soliman. “Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.Am J Cardiol 119, no. 11 (June 1, 2017): 1785–90. https://doi.org/10.1016/j.amjcard.2017.02.045.
O’Neal WT, Sandesara P, Hammadah M, Venkatesh S, Samman-Tahhan A, Kelli HM, et al. Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2017 Jun 1;119(11):1785–90.
O’Neal, Wesley T., et al. “Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.Am J Cardiol, vol. 119, no. 11, June 2017, pp. 1785–90. Pubmed, doi:10.1016/j.amjcard.2017.02.045.
O’Neal WT, Sandesara P, Hammadah M, Venkatesh S, Samman-Tahhan A, Kelli HM, Soliman EZ. Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2017 Jun 1;119(11):1785–1790.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

June 1, 2017

Volume

119

Issue

11

Start / End Page

1785 / 1790

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Rate
  • Stroke Volume
  • Stroke
  • Spironolactone
  • Sex Factors
  • Sex Distribution
  • Risk Factors
  • Risk Assessment